Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a report date of April 14, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| April 12, 2022 | American Depositary Shares (ADSs) | $46.7026 | 4,453.195 | New York Stock Exchange (XNYS) |
Note: The total volume represents the aggregate of four separate transactions executed by different executives on the same date at the same price.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely discloses routine acquisitions of ADSs by executives following the re-investment of dividends paid to shareholders on April 7, 2022.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of specific share transactions.
Important Facts for Investors
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from the automatic re-investment of dividends, not open-market purchases.
- Executives Involved: The transactions involved Dr. H. Barron (Chief Scientific Officer), Mr. J. Ford (SVP and Group General Counsel), Mr. B. McNamara (CEO, GSK Consumer Healthcare), and Shobie Ramakrishnan (Chief Digital and Technology Officer).
- Transaction Details: All four executives purchased shares on April 12, 2022, at a uniform price of $46.7026 per ADS on the NYSE.
- Financial Data: This filing does not provide quarterly or annual financial results; investors should refer to Form 20-F or earnings releases for financial performance.